Testing blood DNA tests in people with localized pancreatic cancer
Tests blood DNA markers to predict cancer return in people with resectable pancreatic cancer.
Plain-language title generated from the registry record
Registry title: Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer
Key facts
- Where
- Aalborg, Aarhus, Copenhagen, Herlev, and Odense, DenmarkSee the 5 sites
Where in Denmark
- Aalborg UniversitetshospitalAalborg, DenmarkTaking people
- Aarhus UniversitetshospitalAarhus, DenmarkTaking people
- Copenhagen University Hospital, RigshospitaletCopenhagen, DenmarkTaking people
- Copenhagen University Hospital Herlev and GentofteHerlev, DenmarkTaking people
- Odense UniversitetshospitalOdense, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Copenhagen University Hospital at Herlev
- Trial code
- NCT05788744
- Record updated
- 27 March 2026
- Original description
The goal of this clinical trial is to investigate if plasma ctDNA and eccDNA before resection for suspicion of pancreatic ductal adenocarcinoma (PDAC) can predict early recurrence and overall survival, and to investigate if plasma ctDNA combined with CT scan and endoscopic ultrasound surveillance increases the median overall survival compared with standard-of-care surveillance.Read full original descriptionShow less
Implementing Non-invasive Circulating Tumor DNA and Circular DNA Analysis in Patients With Localized Pancreatic Cancer to Optimize the Pre- and Postoperative Treatment: Predicting Recurrence and Survival and Changing Prognosis Over Time
The goal of this clinical trial is to investigate if plasma ctDNA and eccDNA before resection for suspicion of pancreatic ductal adenocarcinoma (PDAC) can predict early recurrence and overall survival, and to investigate if plasma ctDNA combined with CT scan and endoscopic ultrasound surveillance increases the median overall survival compared with standard-of-care surveillance.
Inclusion: Sub-study 1: Suspicion of PDAC tumor stage I-III, scheduled for pancreatic resection, with or without preoperative neoadjuvant chemotherapy; Sub-study 2: ; PDAC tumor stage I-III; Has received intended curative resection (R0/R1) of PDAC; No signs of local recurrence or metastatic disease at a CT scan 4 months after the operation.
Exclusion: Other cancers (excluding skin cancer other than melanoma) later than 3 years before inclusion; Patients who are unlikely to comply with the protocol, inability to return for subsequent visits) and/or otherwise considered by the Investigator to be unlikely to complete the study.